The Effects of the Dihydropyridine Bay K 8644 in Guinea-pig Isolated Trachealis
Overview
Authors
Affiliations
In trachea bathed by Krebs solution containing indomethacin 0.8 mumol l-1, Bay K 8644 (0.01-1 mumol l-1) evoked mild spasm. Peak tension was achieved after 10 min and was generally less than 20% of an acetylcholine (ACh) maximum. The effect of Bay K 8644 was not potentiated by addition of 2.5 mmol l-1 potassium chloride (KCl) to the Krebs solution. Bay K 8644 (1 mumol l-1) caused a small potentiation of KCl and tetraethylammonium (TEA). In contrast it did not modify the actions of ACh or histamine. Bay K 8644 (1 mumol l-1) caused a small potentiation of the effect of calcium chloride (CaCl2) tested in trachea bathed by a K+-rich, Ca2+-free, MOPS-buffered physiological salt solution. Organic inhibitors of calcium influx such as nifedipine (0.1 mumol l-1), verapamil (1 mumol l-1) or diltiazem (10 mumol l-1) each caused marked depression of concentration-effect curves to KCl. Bay K 8644 (0.01-1 mumol l-1) provided concentration-dependent protection against this effect in all three cases. Estimation of calcium influx by the lanthanum technique revealed that Bay K 8644 (1 mumol l-1) was able to promote the cellular influx of Ca2+. Intracellular electrophysiological recording showed that Bay K 8644 (1 mumol l-1) caused no change in the resting membrane potential of trachealis cells and no change in the properties of the spontaneous electrical slow waves. However, Bay K 8644 was able to delay the slow wave suppression evoked by 1 mumol l-1 nifedipine. The ability of Bay K 8644 to promote Ca2+ influx and its ability to protect against the effects of several structurally-unrelated inhibitors of Ca2+ influx are consistent with Bay K 8644 acting as an agonist at the dihydropyridine receptor associated with the voltage-operated Ca2+ channel (VOC) of trachealis muscle. By this action it potentiates those spasmogens (KCl, TEA) which act by permitting Ca2+ influx through VOCs. In contrast it has no effect on those spasmogens (ACh, histamine) which principally act to liberate Ca2+ from intracellular sites of sequestration.
Ur Rehman N, Ansari M, Haile T, Karim A, Abujheisha K, Ahamad S Front Pharmacol. 2021; 12:615228.
PMID: 33883992 PMC: 8053776. DOI: 10.3389/fphar.2021.615228.
Allen S, Cortijo J, Foster R, MORGAN G, Small R, Weston A Br J Pharmacol. 1986; 88(2):473-83.
PMID: 3730702 PMC: 1916826. DOI: 10.1111/j.1476-5381.1986.tb10226.x.
Moreland S, Ushay M, Kimball S, Powell J, Moreland R Br J Pharmacol. 1988; 93(4):994-1004.
PMID: 2455580 PMC: 1853869. DOI: 10.1111/j.1476-5381.1988.tb11490.x.
Boyle J, Davies J, Foster R, Good D, Kennedy I, Small R Br J Pharmacol. 1988; 93(2):319-30.
PMID: 2451965 PMC: 1853808. DOI: 10.1111/j.1476-5381.1988.tb11437.x.
Effects of Bay K 8644 on contraction of the human isolated bronchus and guinea-pig isolated trachea.
Advenier C, Naline E, Renier A Br J Pharmacol. 1986; 88(1):33-9.
PMID: 2423176 PMC: 1917117. DOI: 10.1111/j.1476-5381.1986.tb09468.x.